ClinicalTrials.gg

Program

lenacapavir

Also written as “Lenacapavir Tablet”, “Lenacapavir Injection” and “Lenacapavir”.

Its studies are mostly in HIV Infections, led by Gilead Sciences.

Furthest: phase 4, since Oct 26, 202619 company-led studies, 16 open or runningNext primary completion: Mar 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Gilead Sciences1916 open or runningphase 4since Oct 26, 2026Nov 2, 2018Mar 2027phase 2 · NCT06749054

Also a collaborator on its studies: Merck.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 5 studies since Nov 2, 2018.

  1. Aug 2, 2021Phase 3 study in Pre-Exposure Prophylaxis of HIV InfectionNCT04994509 · 5,368 enrolled · South Africa, Uganda
  2. Sep 13, 2021Phase 2 study in HIV-1 InfectionNCT05052996 · 142 enrolled · United States
  3. Aug 5, 2022Phase 3 study in HIV-1-infectionNCT05502341 · 689 enrolled · United States, Argentina, Australia and more
  4. Oct 20, 20232 phase 2 studies in Pre-Exposure Prophylaxis of HIV InfectionNCT06101342, NCT06101329
  5. Mar 20, 2024Phase 3 study in HIV-1-infectionNCT06333808 · 577 enrolled · United States, Argentina, Australia and more
  6. Jul 16, 2024Phase 2 study in Pre-Exposure Prophylaxis of HIV InfectionNCT06513312 · 268 enrolled · France, United Kingdom
  7. Jul 29, 2024Phase 3 study in HIV-1-infectionNCT06532656 · 75 enrolled · United States, Argentina, Italy and more
  8. Dec 19, 2024Phase 2 study in HIV-1-infectionNCT06749054 · 12 planned · United States, South Africa
  9. Jun 24, 2025Phase 3 study in HIV Pre-exposure ProphylaxisNCT07047716 · 339 enrolled · United States
  10. Jun 8, 2026Phase 2 study in HIV-1-infectionNCT07645287 · 175 planned · United States, Australia, Canada and more
  11. Jun 26, 2026Phase 3 study in HIV InfectionsNCT07682961 · 590 planned · United States, Australia, Japan
  12. Jul 13, 2026Phase 3 study in HIV-1-infectionNCT07708727 · 700 planned · United States, Canada, Germany and more
  13. Sep 29, 2026Primary completion moved from 2026-11 to 2030-07Date moved laterphase 3 · +44 months · NCT06532656
  14. Oct 26, 2026Phase 4 study in HIV-1 InfectionNCT07908446 · 400 planned

Ahead

  1. Mar 2027Primary completion: phase 2 study in HIV-1-infectionNCT06749054
  2. Aug 2027Primary completion: phase 2 study in HIV-1-infectionNCT07645287
  3. Jul 2028Primary completion: phase 4 study in HIV-1 InfectionNCT07908446
  4. Sep 2028Primary completion: phase 3 study in HIV Pre-exposure ProphylaxisNCT07047716

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Structural capsid protein inhibitor; Structural capsid protein inhibitor”ChEMBL 37, by rule

Studies

All 19 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07908446HIV-1 Infection4Not yet recruitingJul 2028400
NCT07708727HIV-1-infection · United States, Canada, Germany and more3RecruitingOct 2030700
NCT07682961HIV Infections · United States, Australia, Japan3RecruitingMar 2029590
NCT07645287HIV-1-infection · United States, Australia, Canada and more2RecruitingAug 2027175
NCT07047716HIV Pre-exposure Prophylaxis · United States3Active, not recruitingSep 2028339
NCT06749054HIV-1-infection · United States, South Africa2RecruitingMar 202712
NCT06532656HIV-1-infection · United States, Argentina, Italy and more3Active, not recruitingJul 203075
NCT06513312Pre-Exposure Prophylaxis of HIV Infection · France, United Kingdom2Active, not recruitingMay 28, 2026268
NCT06333808HIV-1-infection · United States, Argentina, Australia and more3Active, not recruitingOct 27, 2025577
NCT06101342Pre-Exposure Prophylaxis of HIV Infection · United States2Active, not recruitingJul 27, 2026181
NCT06101329Pre-Exposure Prophylaxis of HIV Infection · United States2Active, not recruitingJul 22, 2026253
NCT05502341HIV-1-infection · United States, Argentina, Australia and more3Active, not recruitingSep 29, 2025689
NCT05052996HIV-1 Infection · United States2Active, not recruitingDec 19, 2023142
NCT04994509Pre-Exposure Prophylaxis of HIV Infection · South Africa, Uganda3Active, not recruitingMay 27, 20245,368
NCT04925752Pre-Exposure Prophylaxis of HIV Infection · United States, Argentina, Brazil and more3Active, not recruitingAug 21, 20243,292
NCT04811040HIV-1 Infection · United States1CompletedJun 9, 202232
NCT04150068HIV-1-infection · United States, Canada, Dominican Republic and more3Active, not recruitingOct 5, 202072
NCT04143594HIV-1-infection · United States, Dominican Republic, Puerto Rico2CompletedOct 5, 2021183
NCT03739866HIV-1 Infection · United States1CompletedNov 14, 201953

How it is read

Names in the registry

  • “Lenacapavir Tablet”, 7 entries
  • “Lenacapavir Injection”, 6 entries
  • “Lenacapavir”, 5 entries
  • “Oral Lenacapavir”, 4 entries
  • “Subcutaneous Lenacapavir”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.